7AXR image
Entry Detail
PDB ID:
7AXR
Keywords:
Title:
Crystal structure of BRD4(1) bound to the dual BET-HDAC inhibitor LSH24
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2020-11-10
Release Date:
2021-10-06
Method Details:
Experimental Method:
Resolution:
1.50 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Bromodomain-containing protein 4
Chain IDs:A
Chain Length:127
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
J.Med.Chem. 64 14620 14646 (2021)
PMID: 34582215 DOI: 10.1021/acs.jmedchem.1c01119

Abstact

Multitarget drugs are an emerging alternative to combination therapies. In three iterative cycles of design, synthesis, and biological evaluation, we developed a novel type of potent hybrid inhibitors of bromodomain, and extra-terminal (BET) proteins and histone deacetylases (HDACs) based on the BET inhibitor XD14 and well-established HDAC inhibitors. The most promising new hybrids, 49 and 61, displayed submicromolar inhibitory activity against HDAC1-3 and 6, and BRD4(1), and possess potent antileukemia activity. 49 induced apoptosis more effectively than the combination of ricolinostat and birabresib (1:1). The most balanced dual inhibitor, 61, induced significantly more apoptosis than the related control compounds 62 (no BRD4(1) affinity) and 63 (no HDAC inhibition) as well as the 1:1 combination of both. Additionally, 61 was well tolerated in an in vivo zebrafish toxicity model. Overall, our data suggest an advantage of dual HDAC/BET inhibitors over the combination of two single targeted compounds.

Legend

Protein

Chemical

Disease

Primary Citation of related structures